COVID-19 Response

Deploying its MAPS technology to advance COVID-19 vaccine development

Advancing the development of a COVID-19 vaccine

Affinivax is supporting the development of next-generation vaccines by accelerating the use of its patented Multiple Antigen Presenting System (MAPS) technology, which enables high affinity binding of polysaccharides and proteins to uniquely induce a broad and protective B- and T-cell immune response to vaccines.

Blog post

Challenging Vaccine Norms and Clearing a New Path The Affinivax Story

Continuing the fight against other infectious diseases

In addition to COVID-19, Affinivax is applying its platform to develop vaccines designed to provide significantly more protection than existing vaccines (such as Streptococcus pneumoniae), as well as vaccines against multiple healthcare associated infections (such as Klebsiella, Pseudomonas, Clostridium difficile, and Staphylococcus aureus), for which there are no effective immunization strategies today.

About Affinivax

Affinivax is a clinical stage biotechnology company with a next generation Multiple Antigen Presentation System (MAPS) vaccine technology platform.


Hit enter to search or ESC to close